21 CFR Part 211 – cGMP guidelines for Finished pharmaceuticals

Share this article :

In 1962, the US government told the FDA to make sure that all medicines are manufactured using good manufacturing practices (GMP) which should be compliant to FDA 21 CFR Part 210 and 21 CFR 211. This was because there were worries about some medicines being made in a bad way, like when a medicine called thalidomide caused birth defects. The 1962 Drug Amendments brought cGMP, modern quality assurance and control control guideline to drug manufacturing to make sure medicines are safe and high quality.

21 CFR Part 211
21 CFR Part 211

Subpart A – General Provisions
   211.1 – Scope
   211.3 – Definitions

Subpart B – Organization and Personnel
   211.22 – Responsibilities of quality control unit
   211.25 – Personnel qualifications
   211.28 – Personnel responsibilities
   211.34 – Consultants

Subpart C – Buildings and Facilities
   211.42 – Design and construction features
   211.44 – Lighting
   211.46 – Ventilation, air filtration, air heating and cooling
   211.48 – Plumbing
   211.50 – Sewage and refuse
   211.52 – Washing and toilet facilities
   211.56 – Sanitation
   211.58 – Maintenance

Subpart D – Equipment
   211.63 – Equipment design, size, and location
   211.65 – Equipment construction
   211.67 – Equipment cleaning and maintenance
   211.68 – Automatic, mechanical, and electronic equipment
   211.72 – Filters

Subpart E – Control of Components and Drug Product Containers and Closures
   211.80 – General requirements
   211.82 – Receipt and storage of untested components, drug product containers, and closures
   211.84 – Testing and approval or rejection of components, drug product containers, and closures
   211.86 – Use of approved components, drug product containers, and closures
   211.87 – Retesting of approved components, drug product containers, and closures
   211.89 – Rejected components, drug product containers, and closures
   211.94 – Drug product containers and closures

Subpart F – Production and Process Controls
   211.100 – Written procedures; deviations
   211.101 – Charge-in of components
   211.103 – Calculation of yield
   211.105 – Equipment identification
   211.110 – Sampling and testing of in-process materials and drug products
   211.111 – Time limitations on production
   211.113 – Control of microbiological contamination
   211.115 – Reprocessing

Subpart G – Packaging and Labeling Control
   211.122 – Materials examination and usage criteria
   211.125 – Labeling issuance
   211.130 – Packaging and labeling operations
   211.132 – Tamper-evident packaging requirements for over-the-counter (OTC) human drug products
   211.134 – Drug product inspection
   211.137 – Expiration dating

Subpart H – Holding and Distribution
   211.142 – Warehousing procedures
   211.150 – Distribution procedures

Subpart I – Laboratory Controls
   211.160 – General requirements
   211.165 – Testing and release for distribution
   211.166 – Stability testing
   211.167 – Special testing requirements
   211.170 – Reserve samples
   211.173 – Laboratory animals
   211.176 – Penicillin contamination

Subpart J – Records and Reports
   211.180 – General requirements
   211.182 – Equipment cleaning and use log
   211.184 – Component, drug product container, closure, and labeling records
   211.186 – Master production and control records
   211.188 – Batch production and control records
   211.192 – Production record review
   211.194 – Laboratory records
   211.196 – Distribution records
   211.198 – Complaint files

Subpart K – Returned and Salvaged Drug Products
   211.204 – Returned drug products
   211.208 – Drug product salvaging

Also Read : 21 CFR Part 210 – cGMP in Manufacturing, Processing, Packing, or Holding of Drugs; General

ALCOA + 9 Principles for Data Integrity

Leave a comment